Elanco director awarded 4,678 deferred stock units
HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HOOVER R DAVID reported acquisition or exercise transactions in this Form 4 filing.
Elanco Animal Health Inc director R. David Hoover received a grant of 4,678 shares of Common Stock as deferred stock units, described as a pro-rated annual equity award for non-employee board members. The award carried a grant price of $0.00 per share, reflecting its compensation nature rather than a market purchase.
After this grant, Hoover directly holds 111,451 shares of Elanco common stock. He also has indirect holdings reported through the Suzanne A. Hoover Revocable Trust with 15,920 shares and another Revocable Trust with 150,000 shares, providing additional indirect exposure to Elanco shares.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 4,678 | $0.00 | $0.00 |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- F1. Grant of deferred stock units as a pro-rated annual equity award to each of the non-employee members of the Issuer's Board of Directors.
Key Figures
Key Terms
deferred stock units financial
pro-rated annual equity award financial
non-employee members of the Issuer's Board of Directors financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Elanco (ELAN) director R. David Hoover report in this Form 4?
What indirect Elanco (ELAN) holdings are reported for trusts associated with Hoover?
AI-generated analysis. How Rhea-AI works. Not financial advice.